by David V. Sheehan, MD, MBA; Maria Gasior, MD, PhD; Susan L. McElroy, MD; Jana Radewonuk, MSc; Barry K. Herman, MD, MMM; and James Hudson, MD, ScD Dr. Sheehan is
By Anna I. Guerdjikova, PhD, LISW; Stephanie Williams, MS; Thomas J. Blom, MS; Nicole Mori, CNP; and Susan L. McElroy, MD Drs. Guerdjikova and McElroy and Ms. Mori are with
By Katie T. B. Touma, PharmD, BCPP, BCPS, and Jonathan R. Scarff, MD Dr. Touma is with the William Jennings Bryan Dorn VA Medical Center Community-based Outpatient Clinic in Anderson,
By Ann Mcnary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Funding: No funding was provided for the preparation of this article. Disclosures: Ms. McNary
Innov Clin Neurosci. 2018;15(5–6):11–12 Dr. Majeed is an attending psychiatrist with Department of Psychiatry, Natchaug Hospital in Norwich, Connecticut. Dr. Ubaidulhaq is a Pain Medicine Fellow and Dr. Gusa Attending
Innov Clin Neurosci. 2018;15(5–6):11–12 Dr. Bestha is with the Carolinas Healthcare System in Charlotte, North Carolina. Funding/financial disclosures. The author has no conflicts of interest relevant to the content of
Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5
by Amne Borghol, PharmD, BCPS, BCGP; Michael Aucoin, PharmD; Ifeanyichukwu Onor, PharmD, BCPS; Dana Jamero, PharmD, BCOP; and Fadi Hawawini, DO, CMD Drs. Borghol, Onor, and Jamero are with the
by Emily Leppien, PharmD, BCPS; Kimberly Mulcahy, PharmD, BCPS, BCPP; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN; and Lewis Opler, MD, PhD† Drs.
by Khurshid A. Khurshid, MD, FAASM Dr. Khurshid is Clinical Associate Profressor and Chief of the Neuromodulation and Sleep Disorders Program in the Department of Psychiatry at the University of
by Swapnajeet Sahoo, MD; Susanta Kumar Padhy, MD; Neha Singla, MD; and Aakanksha Singh, MD Drs. Sahoo, Singla, and Singh are Senior Residents and Dr. Padhy is Associate Professor in
by Steven D. Targum, MD; Christopher Murphy, PhD; Jibran Khan, BA; Laura Zumpano, BA; Mark Whitlock, PhD; Arthur A. Simen, MD, PhD; and Brendon Binneman, MD† Drs. Targum and Murphy
This ongoing column explores off-label or emerging treatment options, drug development trends, and theoretical concepts in the field of neuroscience. by Anja Srienc, PhD, MD; Puneet Narang, MD; Simrat Sarai,
by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President, Risk Management at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2018;15(3–4):47–51 Funding: No funding was provided for the preparation
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a rapid progression, affecting motor neurons in the brain and spinal cord, ultimately leading to
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Recently, Iwaku et al1 reported a detailed case of olanzapine-related acute-onset Type 1 diabetes with ketoacidosis.1 They concluded that olanzapine sometimes can cause sudden
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Schizophrenia is a chronic and progressive psychiatric disorder requiring long-term treatment with antipsychotics. The use of long-acting injectable antipsychotics (LAI) has been shown to
Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD Dr. Ehlers is with Biogen in Cambridge, Massachusetts. Innov Clin Neurosci. 2018;15(3–4):15–16 Funding: No funding was received for the preparation of this article. Disclosures:
Read More